Ono Pharmaceutical Co., Ltd. (4528.T)

2.204,00 -4,00 (-0,18%) Alla chiusura: 03:15PM JST

Ono Pharmaceutical Co., Ltd.

8-2, Kyutaromachi 1-chome
Chuo-ku
Osaka 541-8564
Japan
81 6 6263 5670
https://www.ono-pharma.com

Settore/i: Healthcare
Settore: Drug Manufacturers - General
Impiegati a tempo pieno: 

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. Gyo Sagara	CEO & Chairman of the Board	137M	N/D	1958
Mr. Toichi Takino Ph.D.	President, COO & Representative Director	N/D	N/D	1968
Mr. Masaki Ito	Corp. Offcr. and Div. Dir. of Corp. Strategy & Planning, Bus. Mgmt., Fin. & Acc. Dept. and Corp. Tax	N/D	N/D	N/D
Takehiro Yamada	Corporate Officer & Senior Director of Risk & Compliance Mgmt. Dept. and Risk Mgmt. Promotion Office	N/D	N/D	N/D
Masayuki Tanigawa	Corporate Officer & Executive Director of Corporate Development & Strategy	N/D	N/D	N/D
Mr. Toshihiro Tsujinaka	Ex. EO, Executive Dir. of Sus. Promotion Corp. Strategy & Planning and Representative Director	N/D	N/D	1964
Hiromu Habashita Ph.D.	Corporate Officer & Deputy Executive Director, Discovery & Research	N/D	N/D	N/D
Kiyoaki Idemitsu	Managing Executive Officer, GM of Development Division & Director	N/D	N/D	1964
Shinji Takai M.D., Ph.D.	Corporate Officer & Head of Medical Affairs	N/D	N/D	N/D
Satoshi Takahagi	Corporate Officer and Executive Director of Sales, Marketing & Primary Care Business Division	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in JPY.

Descrizione

Ono Pharmaceutical Co., Ltd., together with its subsidiaries, produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. It offers Opdivo Intravenous Infusion and Kyprolis Intravenous Injection for malignant tumors; Emend capsules/Proemend intravenous injections for chemotherapy-induced nausea and vomiting; Demser capsules for the symptoms in patients with pheochromocytoma; and Mektovi, Velexbru, and Braftovi capsules for malignant tumors, as well as ADLUMIZ tablets for cancer cachexia. The company also provides Glactiv tablets for type 2 diabetes; Forxiga tablets for diabetes; Onoact Intravenous Infusion for tachyarrhythmia; Opalmon tablets to treat peripheral circulatory disorder; Coralan for chronic heart failure; Orencia injections for rheumatoid arthritis; Rivastach patches for Alzheimer's disease; Ongentys tablets for Parkinson's disease; Parsabiv, an intravenous infusion for dialysis patients; Staybla tablets for overactive bladder; Onon capsules and Dry Syrups for bronchial asthma and allergic rhinitis; and JOYCLU intra-articular injection for the improvement of joint function, as well as Recalbon tablets for osteoporosis. In addition, it develops products for hepatocellular and urothelial carcinoma; ovarian, bladder, prostate, pancreatic, gastric, esophageal, colorectal, thyroid, cell lung, and breast cancer; acute myeloid leukemia; solid tumors; myelodysplastic syndrome; melanoma; T-cell lymphoma; tachyarrhythmia; pemphigus; scleroderma; seizures; diabetic polyneuropathy; neurodegenerative diseases; autoimmune diseases; narcolepsy; and thrombosis. The company has a collaboration with Adimab, LLC to discover novel antibody drugs; a research collaboration with Turbine Ltd. to identify and validate novel oncology targets; Harvard University for validating novel therapeutic targets; and a strategic drug discovery collaboration with Sibylla Biotech in central nervous system disorders. The company was founded in 1717 and is headquartered in Osaka, Japan.

Governance aziendale

L'ISS Governance QualityScore di Ono Pharmaceutical Co., Ltd. al 1 maggio 2024 è 3. I criteri di valutazione fondamentali sono revisione: 1; Consiglio di Amministrazione: 4; diritti degli azionisti: 2; retribuzione: 1.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.